Towa Pharmaceutical announced that the official appointment of executive personnel will be decided at the general shareholders’ meeting scheduled for June 24, 2026, and has announced the tentative candidates for new and reappointed directors.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4553","jir_company_name":"Towa Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-21","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4553-20260521-02.pdf","jir_short_summary":"Towa Pharmaceutical announced that the official appointment of executive personnel will be decided at the general shareholders' meeting scheduled for June 24, 2026, and has announced the tentative candidates for new and reappointed directors.","jir_summary":"### Overview of Executive Personnel Changes\nTowa Pharmaceutical, at today\u2019s board of directors meeting, announced a tentative decision regarding executive personnel changes. The candidates include President and CEO Isao Yoshida, among several others. These candidates are scheduled to be officially appointed at the 70th Annual General Meeting of Shareholders to be held on June 24, 2026. The new appointment includes Akikazu Sakae, who will serve as President and Chief Operating Officer and in charge of the Management Strategy Division, while other directors will be reappointed.\n\n### Impact of Executive Personnel Changes and Future Outlook\nThis executive personnel change aims to strengthen the company\u2019s management structure and promote mid- to long-term business strategies. In particular, the role of Akikazu Sakae as President and COO is expected to play a key role in advancing management strategies. After the formal decision, it is expected that there will be a proactive rotation of directors to enhance corporate governance and support future business development.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#TowaPharmaceutical, #ExecutiveChange, #JapanStocks","jir_key_figures":"Number of director candidates: 8 (including new and reappointed)\nTentative appointment date: May 21, 2026\nScheduled formal decision date: June 24, 2026","jir_meta_title":"\u3010Towa Pharmaceutical\u3011Executive Change Notice | June 2026 Shareholders' Meeting","jir_meta_description":"Towa Pharmaceutical plans to officially decide on executive personnel changes at the shareholders' meeting on June 24, 2026. Details of new and reappointed director candidates are outlined.","jir_og_title":"\u3010Towa Pharmaceutical\u3011Executive Change Notice | June 2026 Shareholders' Meeting","jir_og_description":"Towa Pharmaceutical has announced its executive personnel decisions, with formal approval scheduled for the shareholders' meeting on June 24, 2026. Details of new and reappointed director candidates are provided.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9026,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-53623","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n